Clinical trials: Advanced Disease
Chronic Obstructive Pulmonary Disease (COPD)
Cell Therapy in Advanced Chronic Obstructive Pulmonary Disease Patients
The purpose of this study is to determine whether cell therapy with autologous adult stem cells (from bone marrow and/or fat) is safe in the treatment of advanced Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT02412332
- Testing
- Bone marrow harvesting, Liposuction
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Thyroid Cancer
Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
Differentiated thyroid cancer includes papillary, follicular, Hurthle cell, and C-cell/medullary carcinoma. Even though incidence is relatively low (1% of all neoplasms), a rise in this disease has been recorded in the country…
- Trial name
- NCT02084732
- Testing
- Sorafenib
- Where
- Colombia
- Volunteers
- 35 people
- Sponsor
- Instituto Nacional de Cancerologia, Columbia
Male Breast Cancer, Recurrent Breast Cancer
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This phase I trial studies the side effects and best dose of gemcitabine hydrochloride and mifepristone when given together with carboplatin in treating patients with breast cancer that is metastatic or cannot be removed by…
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT02046421
- Testing
- mifepristone, carboplatin, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of Chicago
Gastric Cancer
Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of first-line chemotherapy with cisplatin and irinotecan in advanced gastric cancer, and try to find out the optimal dosage of combination chemotherapy.
- Trial name
- NCT01444521
- Testing
- irinotecan and cisplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese Academy of Medical Sciences
Advanced Solid Tumors
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
- Trial name
- NCT03861793
- Testing
- ALKS 4230, Pembrolizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 116 people
- Sponsor
- Mural Oncology, Inc
Renal Cell Carcinoma
Sequential Study to Treat Renal Cell Carcinoma
Primary: To evaluate if progression-free survival from first treatment to progression or death during second-line therapy (total PFS) of sorafenib followed by sunitinib is superior compared to sunitinib followed by sorafenib.
- Trial name
- NCT00732914
- Testing
- Sunitinib (Sutent), Sorafenib (Nexavar)
- Where
- Germany
- Volunteers
- 272 people
- Sponsor
- Sponsor GmbH
Prostatic Neoplasms
Radical Prostatectomy Versus Radical Radiotherapy for Locally Advanced Prostate Cancer
This prospective, open randomized clinical trial seeks to investigate whether radical prostatectomy with androgen deprivation therapy improves prostate-cancer specific survival and quality of life in comparison with radical…
- Trial name
- NCT04093375
- Testing
- Radical Prostatectomy, Radical Radiotherapy
- Volunteers
- 600 people
- Sponsor
- Tongji Hospital
TNBC - Triple-Negative Breast Cancer, TNBC
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
This is an open-label, Simon's optimal two-stage design, single-arm, Phase II study with first 6 patients in the safety run-in portion.
- Trial name
- NCT07441512
- Testing
- Inavolisib in Combination With Eribulin
- Volunteers
- 26 people
- Sponsor
- Hu Hai
Non-small Cell Lung Cancer, Older People
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
To observe the effect and toxicity of carbon ion radiotherapy on local advanced non-small cell lung cancer over 75 years old patients. Systemic therapy could be targeted therapy, chemotherapy or immunotherapy.
- Conditions
- Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy, Radiotherapy Side Effect
- Trial name
- NCT06311981
- Testing
- carbon ion radiotherapy, targeted therapy, single regimen chemotherapy in sequence with radiotherapy
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Jian Chen
Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in…
- Conditions
- Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
- Trial name
- DUET-1 (NCT05120271)
- Testing
- CAR-GPC3 T Cells
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Sotio Biotech Inc.
Chronic Kidney Disease (Stages 4 and 5), Chronic Kidney Disease 5D
The Practicality and Utility of Measured vs Estimated GFR in adCKD
The goal of this observational study is to assess if new ways of measuring kidney function can better predict when individuals will become symptomatic due to kidney failure, and whether residual kidney function can be accurately…
- Trial name
- NCT07450534
- Testing
- Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Manchester University NHS Foundation Trust
Pancreatic Neoplasms, Melanoma
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
In this national Phase I dose-escalation study the safety and tolerability of AP 12009 is evaluated in adult patients with advanced tumors known to overproduce TGF-β2, who are not or no longer amenable to established therapies.
- Conditions
- Pancreatic Neoplasms, Melanoma, Colorectal Neoplasms
- Trial name
- NCT00844064
- Testing
- AP 12009
- Where
- 10 sites in Germany
- Volunteers
- 62 people
- Sponsor
- Isarna Therapeutics GmbH
Colorectal Cancer (CRC)
MRD-Guided Surveillance in Locally Advanced Mid-Low Rectal Cancer (SURVEILLANCE-III)
This study aims to explore the relationship between minimal residual disease (MRD) status and disease recurrence in patients with locally advanced mid-low rectal cancer.
- Trial name
- SURIII (NCT06879899)
- Volunteers
- 139 people
- Sponsor
- Fudan University
Acute Myeloid Leukemia, Disorder Related to Bone Marrow Transplantation
Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients
Early reduction of immunosuppressive agents after HLA matched donor transplantation can improve the survival of advanced stage acute myeloid leukemia. single-center, open clinical study
- Trial name
- NCT03150134
- Testing
- Cyclosporine, routine reduction of immunosuppressive drugs(cyclosporine)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Advanced Cancer, Pain
Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing
The purpose of the study is to evaluate if the smartphone app, I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), helps participants with cancer pain manage symptoms and keep track of medications.
- Trial name
- NCT06117709
- Testing
- I-STAMP
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Dana-Farber Cancer Institute
Lung Cancer, Non-Small Cell
A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
This is a phase II study. All patients are stage IV non-squamas non-small cell lung cancer(NSCLC) with malignant pleura effusion, Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Trial name
- NCT06769295
- Testing
- AK112
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sichuan University
Metastatic Breast Cancer
A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to identify the highest tolerable dose of pyrotinib in combination with vinorelbine and to assess the safety and efficacy of the combination in Patients With HER2-Positive Locally Advanced or…
- Trial name
- NCT03997539
- Testing
- Pyrotinib, Treatment of physician's choice, vinorelbine
- Volunteers
- 256 people
- Sponsor
- Sun Yat-sen University
Non-Small Cell Lung Cancer
A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study will assess the safety and tolerability, and make a preliminary assessment of activity, of a combination of pertuzumab and erlotinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT02507375
- Testing
- Erlotinib, Pertuzumab
- Where
- 3 sites in Belgium, Spain and 1 more
- Volunteers
- 17 people
- Sponsor
- Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
This study will test a new potential treatment for advanced esophageal squamous cell cancer (ESCC) for patients whose initial treatment has stopped working.
- Trial name
- NCT07403136
- Testing
- Vebrekotuzumab, PD-1 antibody
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study
In the China extension study, Chinese participants with programmed cell death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) will be randomized to receive single agent pembrolizumab for up to 35 treatments or…
- Trial name
- NCT03850444
- Testing
- pembrolizumab, carboplatin, paclitaxel
- Volunteers
- 262 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.